Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q2 2016 · 10-Q
Revenue$91.24M$91.24M−27.7% vs Q2 2015 Net Income-$10.95M-$10.95MN/M vs Q2 2015 EPS Diluted-$0.27-$0.27N/M vs Q2 2015 Gross Profit-$2,042,000N/M Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,996,000N/M Free Cash Flowderived-$23,028,000N/M Margins · derivedGross margin-2.2%−30.1 pt vs Q2 2015
Operating margin-2.2%−19.2 pt vs Q2 2015
Net margin-12.0%−23.2 pt vs Q2 2015
ended Jun 30, 2016 · filed Aug 5, 2016 · 36 d after period end